Living Medical eTextbook - Hematology - Projects In Knowledge - Insights into Managing Non-Hodgkin B-Cell Lymphoma Table of Contents - Indolent and Aggressive B-Cell NHL—Current Practice and Unmet Needs CME Information

Chapter 2 – Indolent and Aggressive B-Cell NHL—Current Practice and Unmet Needs

Editor-In-Chief
	Stephanie A. Gregory, MD The Elodia Kehm Chair of Hematology Professor of Medicine Director, Section of Hematology Rush University Medical Center/Rush University Chicago, Illinois
Contributing Editor
	John P. Leonard, MD Professor of Medicine Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Weill Cornell Medical College Center for Lymphoma and Myeloma, and Division of Hematology and Medical Oncology Weill Cornell Medical College and New York Presbyterian Hospital New York, New York
top

Activity Goal
The goal of this CME/CE activity is to examine epidemiology and risk factors for B-cell Non-Hodgkin lymphoma (NHL), to distinguish subtypes and prognosis on the basis of disease aggressiveness, the most current classification system, and prognostic indices; and to understand the role of gene expression profiling.

Target Audience
This CME/CE activity is intended for hematologists, oncologists, radiation oncologists, family practice/primary care physicians, nurses, and pharmacists involved in the management, treatment, and care of patients with lymphoma.

Learning Objectives

•	Compare first-line treatment options for indolent B-cell non-Hodgkin lymphoma (NHL) as well as timing of therapy initiation in order to optimize patient outcomes.
•	Evaluate the role of maintenance therapy in follicular lymphoma to prevent or delay disease progression.
•	Formulate treatment strategies for relapsed and refractory indolent B-cell NHL using currently available options in order to optimize outcomes for individual patients.
•	Assess options for first-line and subsequent lines of therapy for aggressive B-cell NHL in order to select the optimal treatment for individual patients.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge^® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge^® designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Information: Nurses
Projects In Knowledge^® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

Upon completion of this course, participants will be awarded 0.77 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.

top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Stephanie A. Gregory, MD, has received salary/honoraria and fees for non-CME services from Cephalon Inc; consulting fees from Amgen, Inc, and Genentech, Inc; and has conducted contracted research (including PI*) from Astellas Pharma US, Inc, Celgene Corporation, Cephalon, Genentech, Inc, GlaxoSmithKline, Immunomedics, NCIC CTG, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals Inc.
*All research funding go to Rush University Medical Center.

John P. Leonard, MD, has received consulting fees from Abbott Laboratories, Biotest, Calistoga Pharmaceuticals, Celgene Corporation, Cell Therapeutics, Inc, Cephalon Inc, GlaxoSmithKline, Hospira, Immunomedics, Inc, Johnson and Johnson, MedImmune, Inc, Millennium Pharmaceuticals, Inc, MorphoSys, sanofi-aventis, and Seattle Genetics.

Susan R. Peck, PhD (medical writer), has disclosed no significant relationships.

Peer Reviewer has disclosed no significant relationships.

Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top

2038.02